Our goal is to support people affected by headache and migraine. We want to increase the success of individual therapy methods and help those affected to manage their illness self-sufficiently.
M-sense started as an offshoot of a research project from the Humboldt University Berlin and we stay true to our origins. We aim to provide fresh impetus for future migraine research. Our focuses are health, quality of life, and patient-centred treatment. In addition to this, we cooperate with many different partners in the health sector who make important contributions to the research on headache disorders.
In November 2018, the e-health project SMARTGEM (“Smartphone-Assisted Migraine Therapy”) was launched. Together with the department of neurology at Charité University Medicine Berlin, we are working on improving the treatment for those affected by migraine. The clinical study is funded by the innovation fund of the Federal Joint Committee. Also directly involved are the headache centres in Halle and Rostock as well as the health insurance providers AOK Nordost, IKK gesund plus, BKK·VBU and BIG. The aim is to investigate whether this new form of care consisting of M-sense and telemedical services (such as patient forum and digital doctor consultation) contribute to the improvement of migraine and the quality of care of people with migraine.
Anyone who has at least 5 migraine days per month and owns a smartphone can participate in SMARTGEM. More information can be found at the SMARTGEM project website.
Everyday, around 100,000 people are prevented from coming to work because of migraine. The same number turn up to work despite their headache and have to struggle through the day. Migraine also prevents people from enjoying an active social life.
Together with BARMER, Deutsche Telekom AG, and Deutsche Post AG, we have started a pilot project with scientific support from Prof. Tobias Kurth (head of the Institute for Public Health at the Charité University Medicine Berlin). We want to show that M-sense reduces headache days and improves quality of life both in the workplace and at home. “The scientific study of the app is unique,” say BARMER about the project.
For the first time, monoclonal antibodies have been used to develop a prophylactic drug that specifically targets migraine attacks. The development has taken almost 20 years and many of those affected hope now that the new medication can reduce their pain. We want to start joint research projects with pharmaceutical companies to support the introduction of the medication.
The goal of this collaboration is to get to know different groups of patient as well as their needs and various treatment requirements in order to develop individual treatment paths.